Pharmacokinetic Profiling in Drug Research

  • ID: 2180448
  • Book
  • 500 Pages
  • John Wiley and Sons Ltd
1 of 4
Informatics and robotics are the workhorses of a technological revolution in drug research. On them are based combinatorial chemistry which yields compounds by the many thousands, and high–throughput bioassays which screen them for activity. The results are avalanches of ′hits′ which invade the databases like swarms of locusts. But far from being a plague, these innumerable compounds become a blessing if properly screened for ′drugability′, i.e., for ′drug–like′ properties such as good pharmacokinetic (PK) behavior. Pharmacokinetic profiling of bioactive compounds has thus become a sine qua non condition for cherry–picking the most promising hits. Just as important, but less visible, are the structure–property and structure–ADME relationships, which emerge from PK profiling and provide useful feedback when designing new synthetic series.

The profiling of ADME properties (absorption, distribution, metabolism, and excretion) is the focus of this book. Many major advances have been made during the last years in biological, physicochemical, or computational strategies. International authorities and practicing experts from academia and industry offer state–of–the–art presentations of concepts, methods, and technologies now in use or development in drug research.

In addition to its 28 chapters, the book includes a CD–ROM containing the invited lectures, oral communications, and posters (in full version) Presented at the Third LogP Symposium, ′Physicochemical and Biological Profiling in Drug Research′, held at the Federal Institute of  Technology (ETH) of Zurich in March 2004.

Note: Product cover images may vary from those shown
2 of 4
Preface

SETTING THE SCENE

Pharmaceutical research: For what, for whom? Science and social policies (D. J. Triggle)

Property–based lead optimization (H. van de Waterbeemd)

PART 2: BIOLOGICAL STRATEGIES

Membranes – from barriers to magic bullets (O. G. Mouritsen)

Cell culture absorption models – state of the art (P. Artursson, P. Matsson)

Metabolic studies in drug research and development (B. Neugnot, M.–J. Bossant, F. Caradec, B. Walther)

In vitro, in vivo and in silico approaches to predict induction of drug metabolism (U. A. Meyer, S. Blättler, C. Gnerre, M. Oscarson, A.–K. Peyer, F. Rencurel, O. Rifki, A. Roth)

Coordination of uptake and efflux transporters in drug disposition (H. Kusuhara, Y. Sugiyama)

The role of plasma protein binding in drug discovery (R. E. Fessey, R. P. Austin, P. Barton, A. M. Davis, M. C. Wenlock)

In vivo pharmacokinetic profiling of drugs (H. Wunderli–Allenspach)

PART 3: PHYSICOCHEMICAL STRATEGIES

Automated parallel synthesis in support of early drug discovery: Balancing accessibility of chemistry with the design of drug–like libraries (C. M. Baldino)

New insights into the lipophilicity of ionized species (G. Caron, G. Ermondi)

Physicochemical and biological profiling in drug research. ElogD(7.4) 20,000 compounds later: refinements, observations and applications (F. Lombardo, M. Y. Shalaeva, B. D. Bissett, N. Chistokhodova)

Lipid bilayers in ADME: Permeation barriers and distribution compartments (S. D. Krämer)

High–throughput solubility, permeability, and the MAD PAMPA model (A. Avdeef)

Correlations between PAMPA permeability and log P (K. Box, J. Comer, F. Huque)

Predicting the intestinal solubility of poorly soluble drugs (A. Glomme, J. März, J. B. Dressman)

Accelerated stability profiling in drug discovery (E. H. Kerns, L. Di)

Physicochemical characterisation of the solid state in drug development (D. Giron)

PART 4: COMPUTATIONAL STRATEGIES

Calculation of lipophilicity: A classification of methods (R. Mannhold)

The concept of property space: The case of acetylcholine (G. Vistoli, A. Pedretti, L. Villa, B. Testa)

Prediction of site of metabolism in humans: Case studies of cytochromes P450 2C9, 2D6 and 3A4 (G. Cruciani, R. Vianello, I. Zamora)

Use of pharmacophores in predictive ADME (O. O. Clement, O. F. Güner)

The BioPrint® approach for the evaluation of ADME–T properties: Application to the prediction of cytochrome P450 2D6 inhibition (R. Gozalbes, F. Barbosa, N. Froloff, D. Horvath)

Using computer reasoning about qualitative and quantitative information to predict metabolism and toxicity (P. Judson)

Physiologically based pharmacokinetic models (T. Lavé, H. Jones, N. Paquerau, P. Poulin, P. Theil, N. Parrott)

Processing of biopharmaceutical profiling data in drug discovery (K. Sugano, R. Saitoh, A. Higashida, H. Hamada)

PART 5: CONCLUDING CHAPTERS

Educational and communication issues related to profiling compounds for their drug–like properties (R. T. Borchardt)

Present and future significance of ADMET profiling in industrial drug research (W. Cautreels, M. de Vries, C. Höfer, H. Koster, L. Turski)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Bernard Testa
Stefanie D. Kr¿mer
Heidi Wunderli–Allenspach
Gerd Folkers
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll